TY - JOUR
T1 - Susceptibility to endemic Aedes-borne viruses among pregnant women in Risaralda, Colombia
AU - Cardona-Ospina, Jaime A.
AU - Trujillo, Adriana M.
AU - Jiménez-Posada, Erika V.
AU - Sepúlveda-Arias, Juan C.
AU - Tabares-Villa, Fredy A.
AU - Altieri-Rivera, Joanne S.
AU - Monsalve, Alejandro
AU - Restrepo-Chica, Juliana
AU - Osorio, Daniela
AU - Espinoza, Daniel
AU - Zhu, Yerun
AU - Castrillón-Spitia, Juan D.
AU - Henao-SanMartin, Valentina
AU - Murillo-Garcia, David R.
AU - Millán, Natalia
AU - Olaya, Sandra X.
AU - Valencia-Montoya, Ana M.
AU - Bedoya-Arias, Hugo A.
AU - Villamizar-Peña, Rhuvi
AU - Gutierrez-Ocampo, Estefanía
AU - Holguin-Rivera, Yeimer
AU - Cortés-Bonilla, Isabella
AU - Cardona-Trujillo, Maria C.
AU - García-Barco, Alejandra
AU - Bonilla-Aldana, D. Katterine
AU - Lagos-Grisales, Guillermo J.
AU - Rodríguez-Morales, Alfonso J.
AU - Collins, Matthew H.
N1 - Funding Information:
NIH 1K22AI137306 (MHC), Thrasher Research Fund (MHC), REDCap is made available through Emory University (UL1 TR000424), Universidad Tecnológica de Pereira (Proyectos de Investigación: “Evaluación de la función y el fenotipo de linfocitos T como indicador de exposición a Zika in-utero”, Código 5-18-3 [2018-2020] and “Evaluación de la respuesta inmune adaptativa de memoria específica durante el embarazo, contra arbovirus endémicos, en un grupo de pacientes embarazadas de La Virginia, Risaralda, Colombia”, Código 5-19-3 [2019-2021]), Minciencias (Contract No 729, 2021).
Funding Information:
The authors have no competing interests to declare. NIH 1K22AI137306 (MHC), Thrasher Research Fund (MHC), REDCap is made available through Emory University (UL1 TR000424), Universidad Tecnológica de Pereira (Proyectos de Investigación: “Evaluación de la función y el fenotipo de linfocitos T como indicador de exposición a Zika in-utero”, Código 5-18-3 [2018-2020] and “Evaluación de la respuesta inmune adaptativa de memoria específica durante el embarazo, contra arbovirus endémicos, en un grupo de pacientes embarazadas de La Virginia, Risaralda, Colombia”, Código 5-19-3 [2019-2021]), Minciencias (Contract No 729, 2021). All research was performed consistent with the ethical standards established in the 1964 Declaration of Helsinki and the Resolution No 8430 of 1993, which governs health research in Colombia. Written informed consent was obtained from each patient in her native Spanish language. This study protocol was approved by the Bioethics Committee of Universidad Tecnológica de Pereira (Acta No. 22 Punto 03, Numeral 02, del 28 de noviembre de 2016) and Comité de Ética en Investigación, Institución Universitaria Visión de las Américas (Acta No 88 del 23 de Junio de, 2021). The study was initiated under approval by the Institutional Review Board of the University of North Carolina, Chapel Hill (17-1567) and continued under the Emory University IRB (103255 and 00106096). The dataset supporting the conclusions of this article is included within the article and its Supplementary files.
Publisher Copyright:
© 2022
PY - 2022/9
Y1 - 2022/9
N2 - Objectives: Aedes-borne viruses (ABV) affect humans on every inhabited continent and frequently cause epidemics. Recent epidemics of chikungunya and Zika viruses (ZIKV) highlight that preparedness for future epidemics requires assessment of susceptibility, particularly among high-risk groups. We sought to determine immunity against the three major circulating ABV among pregnant women in an ABV-endemic area of Colombia. Methods: A cross-sectional seroprevalence study was performed, enrolling women presenting to Labor and Delivery. Cord blood and maternal peripheral blood samples were obtained. IgG seroprevalence to flaviviruses and chikungunya was determined by ELISA. An abbreviated neutralization test was used to estimate the frequency and magnitude of immunity to Zika and four dengue serotypes. Cluster analyses explored epidemiologic factors associated with seroprevalence. Results: Most women exhibited high levels of neutralizing antibodies to one or more ABV; however, nearly 20% were seronegative for flaviviruses. Our research took place after the epidemic peak of the ZIKV outbreak in Colombia in 2016. However, only 20% of pregnant women had high levels of Zika-neutralizing antibodies consistent with likely protective immunity to ZIKV. Conclusion: Hence, a high proportion of pregnant women in Risaralda remain susceptible to one or more ABV including the teratogenic ZIKV, indicating a risk for future epidemics in this region.
AB - Objectives: Aedes-borne viruses (ABV) affect humans on every inhabited continent and frequently cause epidemics. Recent epidemics of chikungunya and Zika viruses (ZIKV) highlight that preparedness for future epidemics requires assessment of susceptibility, particularly among high-risk groups. We sought to determine immunity against the three major circulating ABV among pregnant women in an ABV-endemic area of Colombia. Methods: A cross-sectional seroprevalence study was performed, enrolling women presenting to Labor and Delivery. Cord blood and maternal peripheral blood samples were obtained. IgG seroprevalence to flaviviruses and chikungunya was determined by ELISA. An abbreviated neutralization test was used to estimate the frequency and magnitude of immunity to Zika and four dengue serotypes. Cluster analyses explored epidemiologic factors associated with seroprevalence. Results: Most women exhibited high levels of neutralizing antibodies to one or more ABV; however, nearly 20% were seronegative for flaviviruses. Our research took place after the epidemic peak of the ZIKV outbreak in Colombia in 2016. However, only 20% of pregnant women had high levels of Zika-neutralizing antibodies consistent with likely protective immunity to ZIKV. Conclusion: Hence, a high proportion of pregnant women in Risaralda remain susceptible to one or more ABV including the teratogenic ZIKV, indicating a risk for future epidemics in this region.
KW - Aedes-borne viruses
KW - Chikungunya
KW - Dengue
KW - Pregnancy
KW - Seroprevalence
KW - Zika
UR - http://www.scopus.com/inward/record.url?scp=85135822219&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2022.07.017
DO - 10.1016/j.ijid.2022.07.017
M3 - Artículo
C2 - 35817285
AN - SCOPUS:85135822219
SN - 1201-9712
VL - 122
SP - 832
EP - 840
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -